08:37 AM EST, 11/21/2024 (MT Newswires) -- NovoCure ( NVCR ) said Thursday that the US Food and Drug Administration approved its new Head Flexible Electrode transducer arrays for use with Optune Gio, a wearable device for treating glioblastoma multiforme brain cancer in adults.
The company said the redesigned arrays, made with flexible polymer materials, are thinner and lighter than previous models.
Novocure ( NVCR ) said it plans to transition US users to the upgraded arrays through the first half of 2025.